Literature DB >> 7708731

Transferrin-antibody fusion proteins are effective in brain targeting.

S U Shin1, P Friden, M Moran, T Olson, Y S Kang, W M Pardridge, S L Morrison.   

Abstract

In the present study, the receptor binding potential of transferrin (Tf) was linked to an antibody binding specificity. Human Tf was fused to mouse-human chimeric IgG3 at three positions: at the end of heavy chain constant region 1 (CH1), after the hinge, and after CH3. The resulting Tf-antibody fusion proteins were able to bind antigen and the Tf receptor. The CH3-Tf fusion protein showed no complement-mediated cytolysis but possessed IgG receptor I (Fc gamma RI) binding activity. Most importantly, all of the fusion proteins demonstrated significant uptake into brain parenchyma, with 0.3% of the injected dose of the hinge-Tf fusion protein rapidly targeted to the brain. Recovery of iodinated CH3-Tf fusion protein from the brain parenchyma demonstrated that the fusion proteins can cross the blood-brain barrier intact. The binding specificity of these fusion proteins can be used for brain delivery of noncovalently bound ligands, such as drugs and peptides, or for targeting antigens present within the brain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7708731      PMCID: PMC42310          DOI: 10.1073/pnas.92.7.2820

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  Receptor-mediated peptide transport through the blood-brain barrier.

Authors:  W M Pardridge
Journal:  Endocr Rev       Date:  1986-08       Impact factor: 19.871

2.  Recombinant polymeric IgG: an approach to engineering more potent antibodies.

Authors:  R I Smith; S L Morrison
Journal:  Biotechnology (N Y)       Date:  1994-07

3.  Similarities between the transferrin receptor proteins on human reticulocytes and human placentae.

Authors:  C A Enns; H H Sussman
Journal:  J Biol Chem       Date:  1981-12-25       Impact factor: 5.157

4.  Structural features of the cell surface receptor for transferrin that is recognized by the monoclonal antibody OKT9.

Authors:  C Schneider; R Sutherland; R Newman; M Greaves
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

5.  Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents.

Authors:  A Ciechanover; A L Schwartz; A Dautry-Varsat; H F Lodish
Journal:  J Biol Chem       Date:  1983-08-25       Impact factor: 5.157

6.  Electrical resistance of brain microvascular endothelium.

Authors:  C Crone; S P Olesen
Journal:  Brain Res       Date:  1982-06-03       Impact factor: 3.252

7.  Characterization of a human macrophage-like cell line stimulated in vitro: a model of macrophage functions.

Authors:  J W Larrick; D G Fischer; S J Anderson; H S Koren
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

8.  Comparison of various methods for delivering radiolabeled monoclonal antibody to normal rat brain.

Authors:  D E Bullard; M Bourdon; D D Bigner
Journal:  J Neurosurg       Date:  1984-11       Impact factor: 5.115

9.  Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors.

Authors:  E A Neuwelt; S I Rapoport
Journal:  Fed Proc       Date:  1984-02

10.  Transferrin receptor on endothelium of brain capillaries.

Authors:  W A Jefferies; M R Brandon; S V Hunt; A F Williams; K C Gatter; D Y Mason
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

View more
  24 in total

Review 1.  Pharmaceutical strategies utilizing recombinant human serum albumin.

Authors:  Victor Tuan Giam Chuang; Ulrich Kragh-Hansen; Masaki Otagiri
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

Review 2.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

Review 3.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  In vitro and initial in vivo evaluation of (68)Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells.

Authors:  Carmen Wängler; Dina Nada; Georg Höfner; Simone Maschauer; Björn Wängler; Stephan Schneider; Esther Schirrmacher; Klaus T Wanner; Ralf Schirrmacher; Olaf Prante
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

5.  In vivo role of B lymphocytes in somatic transgene immunization.

Authors:  S Xiong; M Gerloni; M Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 6.  Pharmacokinetics of recombinant bifunctional fusion proteins.

Authors:  Xiaoying Chen; Jennica L Zaro; Wei-Chiang Shen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-03-20       Impact factor: 4.481

Review 7.  Developing therapeutic antibodies for neurodegenerative disease.

Authors:  Y Joy Yu; Ryan J Watts
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

8.  Mass spectrometry-guided optimization and characterization of a biologically active transferrin-lysozyme model drug conjugate.

Authors:  Son N Nguyen; Cedric E Bobst; Igor A Kaltashov
Journal:  Mol Pharm       Date:  2013-04-10       Impact factor: 4.939

9.  3D single molecule tracking with multifocal plane microscopy reveals rapid intercellular transferrin transport at epithelial cell barriers.

Authors:  Sripad Ram; Dongyoung Kim; Raimund J Ober; E Sally Ward
Journal:  Biophys J       Date:  2012-10-02       Impact factor: 4.033

10.  Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats.

Authors:  Nurmamet Amet; Wei Wang; Wei-Chiang Shen
Journal:  J Control Release       Date:  2009-09-15       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.